Reina N. Fuji, Ph.D. - Publications

Affiliations: 
2005 Cornell University, Ithaca, NY, United States 
Area:
Signal Transduction Mechanisms

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Fuji RN, Flagella M, Baca M, Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, Katavolos P, Lee DW, Lewin-Koh SC, Lin T, Liu X, Liu S, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science Translational Medicine. 7: 273ra15. PMID 25653221 DOI: 10.1126/scitranslmed.aaa3634  0.56
2014 Estrada AA, Chan BK, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chen H, Dominguez SL, Dotson J, Drummond J, Flagella M, Fuji R, Gill A, Halladay J, Harris SF, et al. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. Journal of Medicinal Chemistry. 57: 921-36. PMID 24354345 DOI: 10.1021/jm401654j  0.56
2014 Erickson JW, Antonyak MA, Fuji R, Cerione RA. Rho GTPases in cancer Ras Superfamily Small G Proteins: Biology and Mechanisms 1: General Features, Signaling. 421-438. DOI: 10.1007/978-3-7091-1806-1_18  0.56
2013 Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Science Translational Medicine. 5: 183ra57, 1-12. PMID 23636093 DOI: 10.1126/scitranslmed.3005338  0.56
2013 Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, Young C, Ljumanovic N, Stainton S, Ulufatu S, Fourie A, Kozak KR, Fuji R, Polakis P, Khawli LA, et al. An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2. British Journal of Pharmacology. 168: 445-57. PMID 22889168 DOI: 10.1111/j.1476-5381.2012.02138.x  0.56
2012 Estrada AA, Liu X, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chan BK, Chen H, Ding X, DiPasquale AG, Dominguez SL, Dotson J, Drummond J, Flagella M, Flynn S, ... Fuji R, et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. Journal of Medicinal Chemistry. 55: 9416-33. PMID 22985112 DOI: 10.1021/jm301020q  0.56
2012 Polson AG, Fuji RN. The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients. British Journal of Pharmacology. 166: 1600-2. PMID 22364106 DOI: 10.1111/j.1476-5381.2012.01916.x  0.56
2012 Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, ... ... Fuji RN, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nature Biotechnology. 30: 184-9. PMID 22267010 DOI: 10.1038/nbt.2108  0.56
2010 Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, Cerione RA. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 18: 207-19. PMID 20832749 DOI: 10.1016/j.ccr.2010.08.009  0.56
2010 Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4769-78. PMID 20805300 DOI: 10.1158/1078-0432.CCR-10-0987  0.56
2010 Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, Yu SF, Du C, Fuh F, Tan C, Wu Y, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia. 24: 1566-73. PMID 20596033 DOI: 10.1038/leu.2010.141  0.56
2010 Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio ALB, Dias SMG, Dang CV, Cerione RA. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation Cancer Cell. 18: 397. DOI: 10.1016/j.ccr.2010.10.011  0.56
2009 Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Molecular Cancer Therapeutics. 8: 2937-46. PMID 19808977 DOI: 10.1158/1535-7163.MCT-09-0369  0.56
2009 Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Research. 69: 2358-64. PMID 19258515 DOI: 10.1158/0008-5472.CAN-08-2250  0.56
2006 Wakshlag JJ, McNeill CJ, Antonyak MA, Boehm JE, Fuji R, Balkman CE, Zgola M, Cerione RA, Page RL. Expression and activity of transglutaminase II in spontaneous tumours of dogs and cats. Journal of Comparative Pathology. 134: 202-10. PMID 16615935 DOI: 10.1016/j.jcpa.2005.11.001  0.56
2005 Fuji RN, Patton KM, Steinbach TJ, Schulman FY, Bradley GA, Brown TT, Wilson EA, Summers BA. Feline systemic reactive angioendotheliomatosis: eight cases and literature review. Veterinary Pathology. 42: 608-17. PMID 16145207 DOI: 10.1354/vp.42-5-608  0.56
2003 Lin Q, Fuji RN, Yang W, Cerione RA. RhoGDI is required for Cdc42-mediated cellular transformation. Current Biology : Cb. 13: 1469-79. PMID 12956948 DOI: 10.1016/S0960-9822(03)00613-4  0.56
Show low-probability matches.